Sugi Predict

Sugi Predict / Compounds / SCHEMBL14241985

SCHEMBL14241985

SCHEMBL14241985

CNC(=O)COc1ccc(B2OC(C)(C)C(C)(C)O2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 5/20 0.59
▸ AAK1 Q2M2I8 1/20 0.48
▸ CA1 P00915 2/20 0.48
▸ CA2 P00918 2/20 0.48
▸ CA9 Q16790 2/20 0.48
▸ KMT2A Q03164 2/20 0.44
▸ PKM P14618 1/20 0.44
▸ RECQL P46063 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ DGAT1 O75907 1/20 0.43
▸ LPL P06858 2/20 0.42
▸ LIPG Q9Y5X9 2/20 0.42
▸ CA12 O43570 1/20 0.41
▸ CA3 P07451 1/20 0.41
▸ CA4 P22748 1/20 0.41
▸ CA6 P23280 1/20 0.41
▸ CA5A P35218 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ CA5B Q9Y2D0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21217992 0.85 HIF1A (0.56) HIF1AAAK1CA1CA2CA9
SCHEMBL28571132 0.84 HIF1A (0.54) HIF1AAAK1CA1CA2CA9
SCHEMBL14241706 0.84 HIF1A (0.52) HIF1AKMT2ALPLLIPG
SCHEMBL578525 0.84 HIF1A (0.53) HIF1AAAK1CA1CA2CA9
SCHEMBL1572955 0.84 HIF1A (0.56) HIF1AAAK1CA1CA2CA9
SCHEMBL24968762 0.83 SMN1; SMN2 (0.59) HIF1AAAK1CA1CA2CA9
SCHEMBL5956627 0.82 CA1 (0.54) HIF1AAAK1CA1CA2CA9
SCHEMBL4782682 0.80 HIF1A (0.53) HIF1AAAK1CA1CA2CA9
SCHEMBL27165341 0.80 SMN1; SMN2 (0.52) HIF1AAAK1CA1CA2CA9
SCHEMBL28493635 0.79 AAK1 (0.47) HIF1AAAK1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10052330-B2 Substituted pyrido[3,4-b]pyrazines as Syk inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2018-08-21 — — US disclosed
EP-2718293-B1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LTD (CN) 2017-10-25 — — EP disclosed
EP-2718293-B1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LTD (CN) 2017-10-25 — — EP disclosed
US-20170152258-A9 Substituted Pyridopyrazines as Syk Inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2017-06-01 — — US disclosed
US-20170152258-A9 Substituted Pyridopyrazines as Syk Inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2017-06-01 — — US disclosed
US-20170152258-A9 Substituted Pyridopyrazines as Syk Inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2017-06-01 — — US disclosed
US-20160324864-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED 2016-11-10 — — US disclosed
US-20160324864-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED 2016-11-10 — — US disclosed
US-9434726-B2 Substituted pyrido[3,4-b]pyrazines as Syk inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2016-09-06 — — US disclosed
US-9434726-B2 Substituted pyrido[3,4-b]pyrazines as Syk inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2016-09-06 — — US disclosed
US-20150307491-A1 SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2015-10-29 — — US disclosed
US-20150307491-A1 SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2015-10-29 — — US disclosed
US-20150307491-A1 SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2015-10-29 — — US disclosed
EP-2928888-A1 SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS Hutchison Medipharma Limited (CN) 2015-10-14 — — EP disclosed
WO-2014086316-A1 SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2014-06-12 — — WO disclosed
WO-2014086316-A1 SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2014-06-12 — — WO disclosed
US-20140121200-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2014-05-01 — — US disclosed
US-20140121200-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2014-05-01 — — US disclosed
WO-2012167423-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2012-12-13 — — WO disclosed
WO-2012167733-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2012-12-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160324864-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS SYK, BTK, LYN HIF1A 4482/4885AAK1 1520/4885CA1 4845/4885
US-20150307491-A1 SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS SYK, BTK, LYN HIF1A 4555/4885AAK1 1621/4885CA1 4792/4885
US-20170152258-A9 Substituted Pyridopyrazines as Syk Inhibitors SYK, BTK, LYN HIF1A 4555/4885AAK1 1621/4885CA1 4792/4885
US-10052330-B2 Substituted pyrido[3,4-b]pyrazines as Syk inhibitors SYK, BTK, TYRO3 HIF1A 4581/4885AAK1 1660/4885CA1 4814/4885
US-20140121200-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS SYK, BTK, LYN HIF1A 4194/4885AAK1 1165/4885CA1 4829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.